About GSK Vaccines
GlaxoSmithKline Vaccines (GSK Vaccines), the vaccine division of the GSK Group, is a global vaccine research, development and production company, at the cutting edge of innovation in the fight against the
most deadly infections and diseases. It is made up of a team of experts whose mission is to devote themselves to developing innovative prophylactic and therapeutic vaccines for the world. This society is indeed pioneering potential new oncologic treatments with our Antigen Specific Cancer Immunotherapies (ASCI) which target a variety of tumor types including lung cancer (NSCLC) and skin cancer (melanoma).
Headquartered in Belgium, GSK Vaccines employs over 12.000 people worldwide, of which 7,500 in its three Belgian sites: Rixensart, Wavre and Gembloux. GSK Vaccines’ global production network is in the midst of becoming the largest in the entire vaccines industry; 15 production sites strategically positioned around the world manufacture, formulate, fill, pack, check and deliver over a billion doses of about 30 different vaccines. GSK Vaccines distributed more than 1.4 billion vaccines to 179 countries last year, of which 70% were distributed to disadvantage regions at preferential prices. GSK Vaccines is the only company to work simultaneously on the three WHO priority diseases: AIDS, Tuberculosis and Malaria and is a key supplier of international organisations such as GAVI and UNICEF and collaborates with country decision-makers to develop vaccination policies and to ensure that the vaccines are available for everyone.
Marcel Laubacher as Vice-President Procurement and Supply Chain Management together with his team are directly collaborating with the Chair. Several members of the GSK Vaccines procurement team are involved as subject matter experts in teaching. GSK Vaccines Procurement manages all global spend of the vaccines division in areas like production, services, R&D clinical and Capex. The global team consists of a 100 buyers from 15 nationalities and has a strong perforance in value contribution. The GSK Vaccines Procurement’s mission is to support the business growth ambition and to generate value by:
- Continually improving value for money
- Ensuring a reliable supply, service and quality
- Challenging business processes, complexity and all expenditures
- Reducing risk
for all goods and services purchased.
The team’s vision is to champion the value capture from the supply market through partnership with vendors and internal clients.
GSK Vaccines in 2010
- 1.4 billion vaccine doses distributed in 2010 to 179 countries – 70% to disadvantage regions at preferential prices
- Over 30 marketed vaccines available worldwide
- Over 20 vaccines in clinical development
- 12.000 employees worldwide
- Over 1,600 passionate scientists
- £4.3 billion sales* (+15% compared to 2009)
- Global manufacturing network: 15 sites around the globe
- 1 billion euro investments in vaccines – ½ directly invested in Belgium
More info on www.gsk.com